Clinical Trial Update: Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ASP7517 alone and in combination with pembrolizumab in adults with advanced cancers expressing WT1 antigen; the study is completed and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• ASP7517
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Advanced Malignancies, Advanced Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-08-08